TPWA
CYTK icon

Twin Peaks Wealth Advisors’s Cytokinetics CYTK Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-152
Closed -$10K – 703
2026
Q1 		$10K Buy
+152
New +$9.66K ﹤0.01% 1070
2025
Q3 		– Sell
-108
Closed -$3.71K – 629
2025
Q2 		$3.71K Buy
+108
New +$3.76K ﹤0.01% 1436

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's CYTK Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 152 shares — an estimated $10K sold.

Twin Peaks Wealth Advisors first reported a position in CYTK in Q2 2025 and held it in 2 quarters. The position peaked at $10K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 152 Cytokinetics shares in Q2 2026, an estimated $10K.
  • Twin Peaks Wealth Advisors first reported a position in Cytokinetics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Cytokinetics position peaked at $10K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.